Hologic Inc.

76.66+0.6700+0.88%Vol 1.73M1Y Perf 84.39%
Apr 16th, 2021 16:00 DELAYED
BID74.21 ASK77.92
Open76.68 Previous Close75.99
Pre-Market- After-Market76.66
 - -  - -%
Target Price
86.00 
Analyst Rating
Moderate Buy 2.00
Potential %
12.18 
Finscreener Ranking
★★★★+     56.66
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     57.91
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     71.97
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap19.75B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
81.03 
Earnings Date
28th Apr 2021

Today's Price Range

75.3776.75

52W Range

41.0385.00

5 Year PE Ratio Range

-91.4092.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.12%
1 Month
6.96%
3 Months
0.74%
6 Months
14.59%
1 Year
84.39%
3 Years
98.24%
5 Years
111.94%
10 Years
249.25%

TickerPriceChg.Chg.%
HOLX76.660.67000.88
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
2.00
2.50
0.45
0.85
16.50
Leverage Ratio 2.50
ProfitabilityValueIndustryS&P 500US Markets
65.60
40.80
49.00
13.10
33.95
RevenueValueIndustryS&P 500US Markets
3.78B
14.67
5.61
6.12
Earnings HistoryEstimateReportedSurprise %
Q01 20212.142.8633.64
Q04 20201.222.0769.67
Q03 20200.360.75108.33
Q02 20200.540.575.56
Q01 20200.610.610.00
Q04 20190.650.650.00
Q03 20190.610.633.28
Q02 20190.570.581.75
Earnings Per EndEstimateRevision %Trend
3/2021 QR2.6134.54Positive
6/2021 QR1.8018.42Positive
9/2021 FY8.9024.13Positive
9/2022 FY5.078.10Positive
Next Report Date28th Apr 2021
Estimated EPS Next Report2.61
Estimates Count8
EPS Growth Next 5 Years %15.40
Volume Overview
Volume1.73M
Shares Outstanding257.66M
Trades Count19.87K
Dollar Volume189.08M
Avg. Volume1.96M
Avg. Weekly Volume1.78M
Avg. Monthly Volume1.67M
Avg. Quarterly Volume1.98M

Hologic Inc. (NASDAQ: HOLX) stock closed at 76.66 per share at the end of the most recent trading day (a 0.88% change compared to the prior day closing price) with a volume of 1.76M shares and market capitalization of 19.75B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5814 people. Hologic Inc. CEO is Stephen P. Macmillan.

The one-year performance of Hologic Inc. stock is 84.39%, while year-to-date (YTD) performance is 5.26%. HOLX stock has a five-year performance of 111.94%. Its 52-week range is between 41.03 and 85, which gives HOLX stock a 52-week price range ratio of 81.03%

Hologic Inc. currently has a PE ratio of 14.00, a price-to-book (PB) ratio of 5.80, a price-to-sale (PS) ratio of 5.07, a price to cashflow ratio of 13.50, a PEG ratio of 2.32, a ROA of 19.19%, a ROC of 25.81% and a ROE of 48.39%. The company’s profit margin is 33.95%, its EBITDA margin is 49.00%, and its revenue ttm is $3.78 Billion , which makes it $14.67 revenue per share.

Of the last four earnings reports from Hologic Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.61 for the next earnings report. Hologic Inc.’s next earnings report date is 28th Apr 2021.

The consensus rating of Wall Street analysts for Hologic Inc. is Moderate Buy (2), with a target price of $86, which is +12.18% compared to the current price. The earnings rating for Hologic Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Hologic Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Hologic Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.54, ATR14 : 2.79, CCI20 : 141.51, Chaikin Money Flow : 0.11, MACD : -0.71, Money Flow Index : 77.33, ROC : 3.78, RSI : 49.72, STOCH (14,3) : 89.46, STOCH RSI : 1.00, UO : 56.44, Williams %R : -10.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Hologic Inc. in the last 12-months were: Allison P. Bebo (Sold 6 100 shares of value $512 778 ), Benjamin J. Cohn (Option Excercise at a value of $709 146), Benjamin J. Cohn (Sold 26 339 shares of value $1 992 182 ), Christiana Stamoulis (Option Excercise at a value of $249 113), Christiana Stamoulis (Sold 11 146 shares of value $824 804 ), John M. Griffin (Option Excercise at a value of $1 073 940), John M. Griffin (Sold 27 806 shares of value $1 872 989 ), Karleen M. Oberton (Option Excercise at a value of $536 283), Karleen M. Oberton (Sold 15 000 shares of value $937 500 ), Kevin R. Thornal (Option Excercise at a value of $1 013 885), Kevin R. Thornal (Sold 30 757 shares of value $1 963 639 ), Peter J. Valenti (Option Excercise at a value of $550 043), Peter J. Valenti (Sold 20 986 shares of value $1 111 135 ), Sally W. Crawford (Sold 63 900 shares of value $3 322 160 ), Scott T. Garrett (Option Excercise at a value of $1 233 732), Stephen P. Macmillan (Option Excercise at a value of $4 814 551), Stephen P. Macmillan (Sold 190 996 shares of value $9 735 257 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (43.75 %)
7 (43.75 %)
5 (33.33 %)
Moderate Buy
2 (12.50 %)
1 (6.25 %)
1 (6.67 %)
Hold
7 (43.75 %)
8 (50.00 %)
8 (53.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
1 (6.67 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.06
Moderate Buy
2.31

Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

CEO: Stephen P. Macmillan

Telephone: +1 508 263-2900

Address: 250 Campus Drive, Marlborough 01752, MA, US

Number of employees: 5 814

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

61%39%

Bearish Bullish

56%44%

Bearish Bullish

63%37%

News

Stocktwits